Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why CRISPR Therapeutics Stock Sank 50.5% in 2021 and Continues to Fall

TheMotleyFool

0 0

Why CRISPR Therapeutics Stock Sank 50.5% in 2021 and Continues to Fall

Shares of CRISPR Therapeutics (NASDAQ: CRSP) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.